Geneva, Feb. 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119061) titled 'Multicenter, Exploratory Study of Adebrelimab Combined with Apatinib in the Treatment of PD-1 Inhibitor-Pretreated (Progressive Unresectable) Hepatocellular Carcinoma' on Feb. 14.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Yantai Yuhuangding Hospital
Condition:
Hepatocellular carcinoma
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-02-14
Target Sample Size: Experimental group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=297222
Published by HT Digital Content Services with permission ...